Repros Therapeutics, Inc. is a biopharmaceutical company, engages in the development of pharmaceutical products that address serious conditions of the male and female reproductive systems. The company’s lead compound, Proellex, an anti progestin, is in U.S. Phase 2 clinical trial for the treatment of uterine fibroids. Proellex is also in European Phase 2 study for the treatment of endometriosis. Repros Therapeutics other products candidates include Androxal in late clinical development, which is designed to restore testosterone production and is being tested in a Phase 3 clinical trial for the treatment of testosterone deficiency; VASOMAX, a Phentolamine-based product, which is in...